Jonathan Mark Hopper - 11 Feb 2023 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Issuer symbol
VCEL
Transactions as of
11 Feb 2023
Net transactions value
-$24,612
Form type
4
Filing time
14 Feb 2023, 15:09:13 UTC
Previous filing
08 Feb 2023
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $0 +1,625 +3.3% $0.000000 51,037 11 Feb 2023 Direct F1, F2
transaction VCEL Common Stock Tax liability $24,612 -840 -1.6% $29.30 50,197 11 Feb 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Restricted Stock Unit Options Exercise -1,625 -50% 1,625 11 Feb 2023 Common Stock 1,625 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest on February 11, 2024.
F2 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F4 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F5 No expiration date for this type of award.
F6 The Fair Market Value of the vested derivative securities is $29.30 per share.